IVF outcome in anovulatory infertility (WHO group 2)--including polycystic ovary syndrome--following previous unsuccessful ovulation induction

Reprod Biomed Online. 2003 Jul-Aug;7(1):50-8. doi: 10.1016/s1472-6483(10)61728-2.

Abstract

This follow-up study represents IVF treatment characteristics and outcomes in women with World Health Organization (WHO) group 2 anovulatory infertility after previous unsuccessful ovulation induction compared with controls. Furthermore, the possibility of initial screening parameters of these anovulatory women to predict IVF outcome was examined. Twenty-six patients with WHO 2 anovulatory infertility who failed to achieve a live birth following previous induction of ovulation (using clomiphene citrate as first line and exogenous FSH as second line) were compared with 26 IVF patients with tubal infertility matched for age, treatment period and treatment regimen. The WHO 2 patients underwent 49 IVF cycles, whereas the normo-ovulatory controls underwent 46 cycles. In WHO 2 patients 15 cycles were cancelled compared with six cycles in controls (P = 0.04). Cycles were predominantly cancelled due to insufficient response (P = 0.04). In cases in whom the cycle was cancelled, body mass index (BMI) was significantly higher (P < 0.001) in WHO 2 women compared with controls. Overall live birth rates were comparable (P = 0.9). Obese women suffering from WHO 2 anovulatory infertility are at an increased risk of having their IVF cycle cancelled due to insufficient response. Once oocyte retrieval is achieved, live birth rates are comparable with controls.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Body Mass Index
  • Female
  • Fertilization in Vitro / methods*
  • Follicle Stimulating Hormone / administration & dosage
  • Follow-Up Studies
  • Humans
  • Infertility, Female / therapy*
  • Menstrual Cycle
  • Obesity / metabolism
  • Oocytes / metabolism
  • Ovary / drug effects
  • Ovulation
  • Ovulation Induction*
  • Pregnancy
  • Pregnancy Outcome
  • Risk
  • Time Factors
  • Treatment Outcome

Substances

  • Follicle Stimulating Hormone